| INTRODUCTION
Breast cancer is the first most commonly diagnosed cancer and second leading cause of cancer related death in women in the USA. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
[Correction added on February 28, 2017, after first online publication: The affiliation of Lei Gao was changed.]
| Apparatus
The chemiluminescence apparatus of CARIS (Xiamen excellent Maike Medical Instrument Co., Ltd, Xiamen, China) and COBASe601 (Roche)
were utilized in this study. 
| Chemicals and reagents

| Performance validation
Performance of the calibration curve, limit of detection, report- 
| The limit of detection
The mean and standard deviation (SD) of the calibration solution at the level of 0.0 U/mL were determined by 20 consecutive measurements. Subsequently, calculating from the mean+2SD of RLU, based on calibration curve, to achieve the actual concentration correspondingly, which was the limit of detection.
| Reportable range
Reportable range was analyzed by measuring ten replicates of the serum samples, which were at two different levels. Among them, four serum samples at low level were recorded as L1, L2, L3, L4, and three-ones at high level were recorded as H1, H2, H3. To extend the reportable range beyond the upper limit of the kit, 10× dilutions were evaluated in serum sample at high level. Reportable range was determined by the measurement, of which the percent of CVs and relative bias% were within ±10%.
| Accuracy
Assess accuracy by the recovery study. In the recovery study, three solutions were prepared. The first solution was the dilution of calibration solution, the second one was the serum sample of healthy people, and the third one was achieved as follows: 20 μL of first solution was spiked with 180 μL of second one to obtain the mixture. Then, the accuracy was evaluated by measuring the recovery rate.
| Precision
Precision was evaluated by calculating the coefficients of variations (CVs) of within-run and between-run. The experiments were performed using two concentrations of serum samples, which were analyzed twenty times over three lots (lot A, lot B and lot C) respectively.
| Anti-interference capability
To identify if increased concentrations of commonly occurring sample matrix components would interfere with the accuracy of the kit assay, the effect of elevated hemoglobin, bilirubin, triglyceride and rheumatoid factor was evaluated using additional interferences.
Anti-interference capability was analyzed by calculating the relative bias%.
| Cross reaction
Serum samples with CA15-3 <25 U/mL (recorded as negative)
were utilized in the experiments to determine the present of crossreaction in the kit. CA125(5000 U/mL), CA19-9(1000 U/mL), CA242(200 U/mL), AFP(1000 IU/mL), PSA(100 ng/mL) and CY21-1(1000 ng/mL) were spiked individually into the serum samples.
All the substances were assayed and CA15-3 of samples was also detected again.
| Method comparison
Comparison of methods from different manufacturers was also carried out. The level of serum tumor marker CA 15-3 was parallelly evaluated by the kit and Roche kit in our present study including 345 patients, to analyze the correlation between the two kits. The log of measurement of CA15-3 was utilized.
| Plasma and serum
CA15-3 measurement in EDTA plasma and serum was compared by testing 150 matched pairs of EDTA plasma and serum samples with dose values covering the entire reportable range of the assay, and the difference of the results were assayed. The log of detection of CA15-3 was analyzed.
| Statistic analysis
All statistics were completed using the SPSS software (SPSS version 20.0, Chicago, IL, USA) and GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Pearson contingency coefficient was conducted to expound correlation between the testing kit and Roche kit, and the equation was generated by simple linear regression analysis. P<.05
was considered statistically significant.
| RESULTS
| Calibration curve
The represented calibration curve of the analytes was shown in Figure 1 , which presented good linearity. The typical regression equation was Y=0.7914X+4.1032 (R 2 =.990).
| The limit of detection
The limit of detection was 0.0347 U/mL (Table 1 ).
| Reportable range
The results were listed in Tables 2 and 3 , all the CVs% and bias% were all within ±10%. The lower limit of reportable range was directly given by the test concentration of the serum sample. The 10× on-board dilution extended the upper end of the reportable range to 2400 U/mL.
Consequently, the reportable range was 0.5-2400 U/mL.
| Accuracy
The mean recovery percentage ranged from 100.0% to 104.8%, which indicated an acceptable degree of accuracy by the kit. 
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| Precision
=.954, P<.01) (Figure 2A ). On the basis of Bland-Altman analysis, the mean difference between the two methods was −0.0094, and the limits of agreement were −0.18 to 0.16 ( Figure 2C ).
| Plasma and serum
The results indicated a good correlation between the measurement of Bland-Altman analysis demonstrated that the mean difference between the EDTA plasma and serum samples was −0.0063 and that the limits of agreement were −0.20 to 0.18, which demonstrated the satisfactory consistency between the measurement of EDTA plasma and serum samples ( Figure 2D ).
| DISCUSSION
CA15-3 is the tumor-associated biomarker that has been popularly utilized in screening, identification, prognosis or detection breast cancer and it has been approved by the Food and Drug Administration (FDA) as a marker to monitor chemotherapy in advanced breast cancer patients. 16 Optimal care of patients with breast cancer needs to measure CA15-3 and interpret the concentrations in conjunction with other clinical information and laboratory data.
Currently, available quantitative determination kits for CA15-3 measuring in China are mainly purchased from Beckman (chemiluminescent assay kit), Abbott (chemiluminescent assay kit) and Roche (electrochemiluminescence immunoassay kit). Patient testing using these methods requires a high cost because kits above got abroad.
The strategy of breaking the foreign monopoly, reducing the cost of measurement encourages the replacement of the foreign kits. In 
